The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
1/50 - 1/100.
1/1000. Predicted molecular weight: 40 kDa.
Differentiation factor required for dendrite morphogenesis and maintenance in the cerebellar cortex. Transcriptional activator. Binds to the insulin gene E-box.
Involvement in disease
Defects in NEUROD1 are the cause of maturity-onset diabetes of the young type 6 (MODY6) [MIM:606394]. MODY is a form of diabetes that is characterized by an autosomal dominant mode of inheritance, onset in childhood or early adulthood (usually before 25 years of age), a primary defect in insulin secretion and frequent insulin-independence at the beginning of the disease.
Contains 1 basic helix-loop-helix (bHLH) domain.
Phosphorylated. In islet cells, phosphorylated on Ser-274 upon glucose stimulation; which may be required for nuclear localization. In activated neurons, phosphorylated on Ser-335; which promotes dendritic growth.
neurogenic helix loop helix protein NEUROD antibody
Neuronal differentiation 1 antibody
Western blot - Anti-NeuroD1 antibody - Aminoterminal end (ab76685)
Anti-NeuroD1 antibody (ab76685) at 1/100 dilution + HepG2 cell line lysate at 35 µg
Predicted band size : 40 kDa
Immunofluorescence - Anti-NeuroD1 antibody - Aminoterminal end (ab76685)
Immunofluorescence of HepG2 cell labelling NeuroD1 with ab76685. HepG2 cells were fixed with 4% PFA (20 min), permeabilized with Triton X-100 (0.1%, 10 min), then incubated with ab76685 (1:25, 1 h at 37℃). Alexa Fluor® 488 conjugated donkey anti-rabbit antibody (green) was used as the secondary antibody (1:400, 50 min at 37℃). Cytoplasmic actin was counterstained with Alexa Fluor® 555 (red) conjugated Phalloidin (7units/ml, 1 h at 37℃) and nuclei were counterstained with DAPI (blue) (10 µg/ml, 10 min). NeuroD1 immunoreactivity is localised to vesicles.
ab76685, at a 1/50 dilution, staining NeuroD1 in formalin fixed, paraffin embedded human hepatocarcinoma tissue by Immunohistochemistry. A peroxidase conjugated secondary antibody was then used, followed by DAB staining.